when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

LEADING · news · pharmadog

← back to LEADING

News mentioning LEADING

652 stories

28dSTAT+: Medicare Advantage plans shift more costs onto seniors in 2027stat

29dChutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOfiercebiotech

29dPfizer’s eczema drug clears skin in mid-stage trialbiopharma dive

29dFresenius Kabi manufacturing plant hit with FDA warning letter after adverse eventsbiospace

29dOpinion: I studied GLP-1 use in children. The results are reassuringstat

Sep 30, 26U.S. poised to boot legal immigrants from Medicaid, including refugees and sex-trafficking victimsstat

Sep 30, 26FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committeesfda press

Sep 30, 26Lilly builds commercial case for GLP-1 products over Novo with indirect analysesbiospace

Sep 30, 26Kratom and 7-OH should be regulated, experts agree. They’re split on howstat

Sep 30, 26No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reinsbiospace

Sep 30, 26Lilly sets up next-gen obesity battle with full phase 3 retatrutide datafiercebiotech

Sep 29, 26Novo to pay Hengrui up to $2.6B for a once-weekly obesity pillbiopharma dive

Sep 29, 26UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 yearsbiospace

Sep 29, 26Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancerfiercebiotech

Sep 29, 26uniQure stock crashes as Huntington’s gene therapy data weakenfiercebiotech

Sep 29, 26Opinion: Massive SNAP cuts could mean more children are separated from their familiesstat

Sep 29, 26She’s spent two decades talking to parents who don’t vaccinate their children. Here’s what she’s learnedstat

Sep 29, 26Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengruifiercebiotech

Sep 28, 26FDA Approves First Treatment for MCT8 Deficiencyfda press

Sep 28, 26Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitorendpoints

Sep 28, 26FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone diseasebiospace

Sep 28, 26Merck, Daiichi end plans to seek speedy approval of lung cancer ADCbiopharma dive

Sep 28, 26Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADCbiospace

Sep 28, 26Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drugfiercebiotech

Sep 28, 26Precision Neuroscience taps $250M in Series D funding for brain-computer interfacefiercebiotech

Sep 28, 26Opinion: AI is eroding the barriers that kept biological weapons rarestat

Sep 28, 266 immunology targets to sustain a mammoth I&I marketbiospace

Sep 26, 26Opinion: I worked on the CDC investigation of the anthrax letters. 25 years later, are we ready for the next biothreat?stat

Sep 25, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Sep 25, 26Federal judge rolls back landmark disability protectionsstat

← prevpage 5 of 22next →